These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15619388)

  • 1. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
    Warnholtz A; Ostad MA; Heitzer T; Goldmann BU; Nowak G; Munzel T
    Am J Cardiol; 2005 Jan; 95(1):20-3. PubMed ID: 15619388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
    Akbulut M; Ozbay Y; Gundogdu O; Dagli N; Durukan P; Ilkay E; Arslan N
    Curr Med Res Opin; 2004 Nov; 20(11):1759-67. PubMed ID: 15537476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis.
    Kitta Y; Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Ichigi Y; Mende A; Kugiyama K
    J Am Coll Cardiol; 2005 Aug; 46(4):648-55. PubMed ID: 16098430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
    Heitzer T; Ollmann I; Köke K; Meinertz T; Munzel T
    Circulation; 2003 Aug; 108(5):536-41. PubMed ID: 12874186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
    Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
    J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased brachial-ankle pulse wave velocity is associated with impaired endothelial function in patients with coronary artery disease.
    Liu DH; Wang Y; Liao XX; Xu MG; Wang JM; Yang Z; Chen L; Lü MD; Lu K; Tao J
    Chin Med J (Engl); 2006 Nov; 119(22):1866-70. PubMed ID: 17134584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
    Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
    Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
    Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of central retinal artery blood flow and endothelial function in patients with coronary artery disease.
    Wu Y; Li S; Zu X; Du J; Wang F
    Curr Eye Res; 2007 Sep; 32(9):813-7. PubMed ID: 17882714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.
    Steen H; Lehrke S; Wiegand UK; Merten C; Schuster L; Richardt G; Kulke C; Gehl HB; Lima JA; Katus HA; Giannitsis E
    Am Heart J; 2005 Mar; 149(3):564. PubMed ID: 15864217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
    Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial.
    Lavi S; Thorpe K; Luca MC; Liuni A; Floras J; Horlick EM; Ing D; Osten MD; Overgaard CB; Lan J; Parker JD; Cantor WJ; Džavík V
    Can J Cardiol; 2012; 28(2):215-21. PubMed ID: 22281412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery.
    Park KH; Park WJ; Kim MK; Park DW; Park JH; Kim HS; Cho GY
    Am J Cardiol; 2010 Jun; 105(12):1723-7. PubMed ID: 20538121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.